Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain
NCT ID: NCT02439411
Last Updated: 2019-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
135 participants
OBSERVATIONAL
2015-03-03
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib
NCT02314143
Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma
NCT02416232
Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)
NCT04547946
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients
NCT03944356
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
NCT02110355
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dabrafenib
No interventions assigned to this group
Dabrafenib plus Trametinib
Patients treated with Dabrafenib plus Trametinib
Trametinib
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Trametinib
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Grupo Español Multidisciplinar de Melanoma
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Salvador Martín Algarra, M.D., Ph.D.
Role: STUDY_CHAIR
Clinica Universidad de Navarra
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Complejo Hospitalario Torrecárdenas
Almería, Almería, Spain
Hospital Universitario Son Espases
Palma de Mallorca, Balearic Islands, Spain
Instituto Catalán de Oncología Badalona/Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, Spain
Instituto Catalán de Oncología L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, Spain
Corporació Sanitaria Parc Taulí de Sabadell
Sabadell, Barcelona, Spain
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain
Onkologikoa Fundazioa
Donostia / San Sebastian, Guipúzcoa, Spain
Complejo Hospitalario Universitario Insular de Canarias
Las Palmas de Gran Canaria, Las Palmas, Spain
Clínica Universidad Navarra
Pamplona, Navarre, Spain
Hospital Universitario de Navarra
Pamplona, Navarre, Spain
Hospital Clínic de Barcelona
Barcelona, , Spain
Hospital General Universitario de Elche
Elche, , Spain
Instituto Catalán de Oncología Girona/Hospital Universitari Dr. Josep Trueta
Girona, , Spain
Hospital Universitario San Cecilio
Granada, , Spain
Hospital Universitari Arnau de Vilanova
Lleida, , Spain
Hospital 12 de Octubre
Madrid, , Spain
Hospital Universitaria La Princesa
Madrid, , Spain
Hospital Universitario Gregorio Marañón
Madrid, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Hospital Universitario Ramón y Cajal
Madrid, , Spain
Hospital Regional Universitario de Málaga
Málaga, , Spain
Complexo Hospitalario Universitario de Ourense
Ourense, , Spain
Hospital Universitario Central de Asturias
Oviedo, , Spain
Hospital Universitario de Valme
Seville, , Spain
Hospital Virgen de la Salud
Toledo, , Spain
Hospital Clínico Universitario de Valencia
Valencia, , Spain
Hospital General Universitario de Valencia
Valencia, , Spain
Instituto Valenciano de Oncología
Valencia, , Spain
Hospital Miguel Servet
Zaragoza, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Martin Algarra S, Soriano V, Fernandez-Morales L, Berciano-Guerrero MA, Mujika K, Manzano JL, Puertolas Hernandez T, Soria A, Rodriguez-Abreu D, Espinosa Arranz E, Medina Martinez J, Marquez-Rodas I, Rubio-Casadevall J, Ortega ME, Jurado Garcia JM, Lecumberri Biurrun MJ, Palacio I, Rodriguez de la Borbolla Artacho M, Altozano JP, Castellon Rubio VE, Garcia A, Luna P, Ballesteros A, Fernandez O, Lopez Martin JA, Berrocal A, Arance A. Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study. Medicine (Baltimore). 2017 Dec;96(52):e9523. doi: 10.1097/MD.0000000000009523.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GEM1401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.